Search global stocks & ETFs...Ctrl K
Learn Mode
Halozyme Therapeutics IncHALO
$79.45
$2.44 (3.168%)
$77.03
-$2.42 (-3.045%)
HALO
Stock Profile
08-03
Recommended Metric
Score Card
Explore Scores Tab
3.92
Good
Valuation Score
Key Score
3.00
Average
Management
2.00
Bad
Growth
2.00
Bad
Profitability
4.00
Good
Fin. Health
3.00
Average
Dividends
--
--
Analyst
3.00
Average
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$79.45
Baseline
High
$100.80
▲
26.87%
Avg
$87.49
▲
10.12%
Low
$57.57
▼
-27.54%
Analyst Ratings based on 16 Analysts
Strong Buy
213%
Buy
956%
Hold
425%
Sell
106%
Strong Sell
000%
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. The company is headquartered in San Diego, California and currently employs 423 full-time employees. The company went IPO on 2003-01-30. The firm's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The firm licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. The company also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The firm has two commercial proprietary products, Hylenex and XYOSTED. The company also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.Read More